By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11025 Roselle Street
Suite 200
San Diego  California  92121  U.S.A.
Phone: 858-587-5870 Fax: 858-587-5871


Company News
bioTheranostics Announces Collaboration With DeNovo Sciences To Evaluate Its Proprietary Cancer Biomarkers For Use In Liquid Biopsies 10/6/2015 10:49:17 AM
Journal Of The National Comprehensive Cancer Network Review Article Highlights Role Of bioTheranostics’ Breast Cancer Index In Optimizing Endocrine Therapy 9/16/2015 11:56:26 AM
ASCO15: Studies Presented At 2015 ASCO Meeting Demonstrate Predictive Power Of bioTheranostics’ Breast Cancer Index Molecular Test In Endocrine Therapy Decisions 6/1/2015 2:20:30 PM
ASCO Conference Data Show bioTheranostics’ Molecular Tests Significantly Impact Management Of Metastatic Cancer Patients 5/28/2015 11:01:29 AM
bioTheranostics Release: Lifetime’s “The Balancing Act” Show For Women To Discuss The Breast Cancer Index Molecular Test 2/23/2015 11:08:02 AM
bioTheranostics Appoints Key Executives To Leadership Team 1/9/2015 9:28:41 AM
Studies Reinforce Unique Predictive And Prognostic Abilities Of bioTheranostics’ Breast Cancer Index Molecular Test 12/9/2014 1:32:09 PM
bioTheranostics Awarded Medicare Coverage for Breast Cancer Index℠ Molecular Test 10/15/2014 10:42:31 AM
bioTheranostics Appoints Nicolas Barthelemy As President And CEO 10/6/2014 8:04:52 AM
Study Shows Use Of 20/20 GeneSystems, Inc.’ Breast Cancer Indexsm Molecular Test Substantially Lowers Medical Costs For ER+ Breast Cancer Patients Compared With Standard Management 9/11/2014 10:07:53 AM